Dietary flaxseed meal is more protective than soy protein concentrate against hypertriglyceridemia and steatosis of the liver in an animal model of obesity

Journal of the American College of Nutrition

Volumn 22, Issue 2, 2003, Pages 157-164

  Bhathena, Sam J ^a   Hansen, Carl T ^b   Haudenschild, Christian ^c   Latham, Patricia ^d   Ranich, Tedine ^d   Velasquez, Manuel T ^d   Mohamed, Ali I ^e   Ali, Ali A ^f  

^a AGRICULTURAL RESEARCH SERVICE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c HOLLAND LABORATORY   (United States)

^d GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

^e VIRGINIA STATE UNIVERSITY   (United States)

^f Ain Shams University   (Egypt)

Author keywords

Cholesterol; Fatty liver; Flaxseed; Hypertriglyceridemia; Plasma lipids; Soy protein

Indexed keywords

CASEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN; SOYBEAN PROTEIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIETARY INTAKE; DRUG EFFECT; GENETIC MODEL; HYPERTRIGLYCERIDEMIA; LINSEED; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN BLOOD LEVEL; PROTEIN INTAKE; SOYBEAN; STEATOSIS;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CASEINS; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; FATTY LIVER; FLAX; HYPERTRIGLYCERIDEMIA; LIVER; MALE; OBESITY; RATS; RATS, INBRED SHR; SOYBEAN PROTEINS; TRIGLYCERIDES;

ANIMALIA; GLYCINE MAX;

EID: 0037390165     PISSN: 07315724     EISSN: 15411087     Source Type: Journal    
DOI: 10.1080/07315724.2003.10719289     Document Type: Article

References (51)

1. Messina M, Persky V, Setchell KDR, Barnes S: Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 21:113-131, 1994.
2. Adlercreutz CHT, Golden BR, Gorbach SL, Hackerstedt KAV, Watanabe S, Hamalainen EK, Markkanen MH, Makela TH, Wahala KT, Adlercreutz T: Soybean phytoestrogen intake and cancer risk. J Nutr 125:757S-770S, 1995.
3. Setchell KDR: Phytoestrogens: The biochemistry, physiology, and implications for human health of soy phytoestrogens. Am J Clin Nutr 68 :1333S-1348S, 1998.
4. Messina MJ: Legumes and soybeans: overview of their nutritional profiles and health effects. Am J Clin Nutr 70 :439S-450S, 1999.
5. Anderson JW, Smith BM, Washnock CS: Cardiovascular and renal benefits of dry bean and soybean intake. Am J Clin Nutr 70 :464S-474S, 1999.
6. Carroll KK: Review of clinical studies on cholesterol-lowering response to soy protein. J Am Diet Assoc 91:820-827, 1991.
7. Wagner JD, Cefalu WT, Anthony MS, Litwak KN, Zhang L, Clarkson TB: Dietary soy protein and estrogen replacement improve cardiovascular risk factors and decrease aortic cholesteryl ester content in ovariectomized cynomolgous monkeys. Metabolism 46:698-705, 1997.
8. Anderson JW, Johnstone BM, Cook-Newell ME: Meta-analysis of effects of soy protein intake on serum lipids in humans. New Engl J Med 333:276-282, 1995.
9. Crouse JR, Morgan T, Terry JG, Ellis J, Vitolins M, Burke GL: A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones in plasma concentrations of lipids and lipoproteins. Arch Intern Med 159:2070-2076, 1999.
10. Sugano M, Yamada Y, Yoshida K, Hashimoto Y, Matsuo T, Kimoto M: The hypocholesterolemic action of the undigested fraction of soy bean protein in rats. Atherosclerosis 72:115-122, 1988.
11. Anthony MS, Clarkson TB, Waddle DL, Wolfe MS: Effects of soy protein phytoestrogens on cardiovascular risk factors in rhesus monkeys. J Nutr 125:803S-804S, 1995.
12. Morita, T, Oh-hashi A, Takei K, Ikai M, Kasaoka S, Kiriyama S: Cholesterol-lowering effects of soybean, potato and rice proteins depend on their low methionine contents in rats fed a cholesterolfree purified diet. J Nutr 127:470-477, 1997.
13. Food and Drug Administration: Food labeling: health claims; soy protein and coronary heart disease. Food and Drug Administration, HHS. Final rule. Fed Regist 64:57700-57733, 1999.
14. Erdman JW: Soy protein and cardiovascular disease: a statement for healthcare professionals from the Nutrition committee of the AHA. Circulation 102:2555-2559, 2000.
15. Ratnayake WMN, Behrens WA, Fischer PWF, L'Abbe MR, Mongeau R, Beare-Rodgers JL: Chemical and nutritional studies of flax-seed (Variety Linott) in rats. J Nutr Biochem 3:232-240, 1992.
16. Prasad K: Dietary flaxseed in prevention of hypercholesterolemic atherosclerosis. Atherosclerosis 132:69-76, 1997.
17. Cunnane SC, Ganguli S, Menard C, Liede AC, Hamadeh MJ, Chen ZY, Wolever TM, Jenkins DJ: High alpha-linolenic acid flaxseed (Linum usitatissimum): some nutritional properties in humans. Br J Nutr 69:443-453, 1994.
18. Bierenbaum ML, Reichstein R, Watkins TR: Reducing atherogenic risk in hyperlipemic humans with flaxseed supplementation: a preliminary report. J Am Coll Nutr 12:501-504, 1993.
19. Babu US, Mitchell GV, Wiesenfeld P, Jenkins MY, Gowda H: Nutritional and hematological impact of dietary flaxseed and defatted flaxseed meal in rats. Int J Food Sci Nutr 51:109-117, 2000.
20. Michaelis OE IV, Ellwood KC, Judge JM, Schoene NW, Hansen CT: Effect of dietary sucrose on the SHR/N-corpulent rat: a new model for insulin-independent diabetes. Am J Clin Nutr 39:612-618, 1984.
21. Michaelis OE IV, Patrick DH, Hansen CT, Canary JJ, Werner RM, Carswell N: Spontaneous hypertensive/NIH-corpulent rat. Animal model for insulin-independent diabetes mellitus (Type II). Am J Path 123:398-400, 1986.
22. Voyles NR, Powell AM, Timmers KI, Wilkins SD, Bhathena SJ, Hansen C, Michaelis OE IV, Recant L: Reversible impairment of glucose-induced insulin secretion in SHR/N-cp rats. Genetic model of type II diabetes. Diabetes 37:398-404, 1988.
23. Michaelis OE IV, Carswell N, Velasquez MT, Hansen CT: The role of obesity, hypertension, and diet in diabetes and its complication in the spontaneous hypertensive/NIH-corpulent rat. Nutrition 5:56-59, 1989.
24. Velasquez MT, Bhathena SJ, Hansen CT: Leptin and its relation to obesity and insulin in the SHR/N-corpulent rat, a model of type II diabetes mellitus. Int Jnl Exp Diab Res 2:217-223, 2001.
25. Andersen T, Gluud C: Liver morphology in morbid obesity: a literature study. Int J Obes 8:97-106, 1984.
26. Van Steenbergen W, Lanckmans S: Liver disturbances in obesity and diabetes mellitus. Int J Obes Relat Metab Disord 19:S27-S36, 1995.
27. Marceau P, Biron S, Hauld FS, Marceau S, Simard S, Thung SN, Kral JG: Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 84:1513-1517, 1999.
28. Dixon JB, Bhathal PS, O'Brien PE: Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121:91-100, 2001.
29. Reeves PG, Nielsen FH, Fahey Jr GC: AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN- 76A rodent diets. J Nutr 123:1939-1951, 1993.
30. Crouse 3rd JR, Morgan T, Terry JG, Ellis J, Vitolins M, Burke GL: A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins. Arch Intern Med 159:2070-2076, 1999.
31. Jenkins DJ, Kendall CW, Vidgen E, Agarwal S, Rao AV, Rosenberg RS, Diamandis EP, Novokmet R, Mehling CC, Perera T, Griffin LC, Cunnane SC: Health aspects of partially defatted flaxseed, including effects on serum lipids, oxidative measures, and ex vivo androgen and progestin activity: a controlled crossover trial. Am J Clin Nutr 69:395-402, 1999.
32. Haytowitz DB, Matthews RH: "Legumes and Legume Products." Washington DC: US Department of Agriculture, pp 1-15, 1986.
33. U.S. Department of Agriculture, Nutrient Data Research Branch, Nutrition Monitoring Division: "Provisional Table on the Content of Omega-3-Fatty Acids and Other Components in Selected Foods." Hyattsville, MD: Human Nutrition Information Service (Publication HNIS/PT-103), 1988.
34. Oomah BD, Mazza G: Flaxseed proteins-A review. Food Chem 48:109-114, 1993.
35. Bhatty RS: Nutrient composition of whole flaxseed and flaxseed meal. In Cunnane SC, Thompson LU (eds): "Flaxseed in Human Nutrition." Champaign, IL: AOCS Press, pp 22-42, 1995.
36. Prasad K, Mantha SV, Muir AD, Westcott ND: Reduction of hypercholesterolemic atherosclerosis by CDC-flaxseed with very low alpha linolenic acid. Atherosclerosis 136:367-375, 1998.
37. Coward K, Barnes NC, Setchel KDR, Barnes S: Genistein and daidzein, and their a-glycoside conjugates: antitumor isoflavones in soybean foods from American and Asian diets. J Agric Food Chem 41:1961-1967, 1993.
38. Wang H-J, Murphy PA: Isoflavone content in commercial soybean foods. J Agric Food Chem 42:1666-1673, 1994.
39. Anthony MS, Clarkson TB, Hughes Jr CL, Morgan TM, Burke GL: Soy isoflavones improve cardiovascular risk factors without affecting the reproductive system of prepubertal rhesus monkeys. J Nutr 126:43-50, 1996.
40. Sirtori CR, Gianazza E, Manzoni C, Lovati MR, Murphy PA: Role of isoflavones in the cholesterol reduction by soy proteins in the clinic. Am J Clin Nutr 65:166-167, 1997.
41. Kirk EA, Sutherland P, Wang SA, Chait A, LeBoeuf RC: Dietary isoflavones reduce plasma cholesterol and atherosclerosis in C57BL/6 mice but not in LDL receptor-deficient mice. J Nutr 128:954-959, 1998.
42. Potter SM, Baum JA, Teng H, Stillman RJ, Shay NF, Erdman Jr JW: Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr 68: 1375S-1379S, 1998.
43. Washburn S, Burke GL, Morgan T, Anthony M: Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women. Menopause 6:7-13, 1999.
44. Teixeira SR, Potter SM, Weigel R, Hannum S, Erdman Jr JW, Hasler CM: Effects of feeding 4 levels of soy protein for 3 and 6 wk on blood lipids and apolipoproteins in moderately hypercholesterolemic men. Am J Clin Nutr 71:1077-1084, 2000.
45. Thompson LU, Robb P, Serraino M, Cheung F: Mammalian lignan production from various foods. Nutr Cancer 16:43-52, 1991.
46. Kitts DD, Yuan YV, Wijewickreme AN, Thompson LU: Antioxidant activity of the flaxseed secoisolariciresinol diglycoside and its mammalian lignan metabolites enterodiol and enterolactone. Mol Cell Biochem 202:91-100, 1999.
47. Prasad K: Reduction of serum cholesterol and hypercholesterolemic atherosclerosis in rabbits by secoisolariciresinol diglucoside from flaxseed. Circulation 99:1355-1362, 1999.
48. Potter S: Overview of proposed mechanisms for the hypocholesterolemic effect of soy. J Nutr 125:606S-611S, 1996.
49. Osono Y, Nakajima K, Hata Y: Hypertriglyceridemia and fatty liver: clinical diagnosis of fatty liver and lipoprotein profiles in hypertriglyceridemic patients with fatty liver. J Atheroscler Thromb 2 (1):S47-S52, 1995.
50. Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G: Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci 45: 1929-1934, 2000.
51. Fong DG, Nehra V, Lindor KD, Buchman AL: Metabolic and nutritional considerations in nonalcoholic fatty liver. Hepatology 32:3-10, 2000.